Tag: ovarian cancer

1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer compared to no annual screening. 2. The incidence of stage III-IV disease was decreased in the CA125 screening group compared to no annual screening. Evidence Rating Level: 1 (Excellent) Study Rundown: Ovarian cancer has a...
1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer compared to no annual screening. 2. The incidence of stage III-IV disease was decreased in the CA125 screening group compared to no annual screening. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus placebo. 2. Adavosertib plus gemcitabine was associated with more hematological adverse effects, such as neutropenia, versus control. Evidence Rating Level: 1 (Excellent) Study Rundown: Despite advances in the field of oncology, ovarian cancer is...
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus placebo. 2. Adavosertib plus gemcitabine was associated with more hematological adverse effects, such as neutropenia, versus control. Evidence Rating Level: 1 (Excellent) Study Rundown: Despite advances in the field of oncology, ovarian...
1. Breastfeeding was found to be significantly associated with decrease risk of invasive ovarian cancer, including high-grade serous and endometroid cancer. Evidence Rating: 2 (Good) Ovarian cancer is a significant contributor to female mortality, with 5-year survival following diagnosis being less than 50%. Prevention is critical for reducing disease mortality, but...
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial 1. Patients receiving landiolol were more likely to achieve target heart rates of 60-94 following sepsis-related tachyarrhythmia and had significantly reduced incidence of new onset arrhythmia Evidence Rating: 1...
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer. 2. In this phase 3 trial, patients with newly diagnosed advanced ovarian cancer who received niraparib had a significantly longer progression-free survival than those who received...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage ovarian cancer,...
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer. 2. In this phase 3 trial, patients with newly diagnosed advanced ovarian cancer who received niraparib had a significantly longer progression-free survival than those who received...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage...